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Summary
The shelterin complex [1] shapes and protects telomeric
DNA from being processed as double strand breaks
(DSBs) [2, 3]. Here we show that in human undamaged cells,
a fraction of the kinase Chk2, a downstream target of ATM
and mediator of checkpoint responses and senescence
[4, 5], physically interacts with the shelterin subunit TRF2
and colocalizes with this complex at chromosome ends.
This interaction, enhanced by TRF2 binding to telomeric
DNA, inhibits the activation and senescence-induced func-
tion of Chk2 by a mechanism in which TRF2 binding to the
N terminus of Chk2 surrounding Thr68 hinders the phos-
phorylation of this priming site. In response to radiation-
induced DSBs, but not chromatin-remodelling agents, the
telomeric Chk2-TRF2 binding dissociates in a Chk2
activity-dependent manner. Moreover, active Chk2 phos-
phorylates TRF2 and decreases its binding to telomeric
DNA repeats, corroborating the evidences on the specific
TRF2 relocalization in presence of DSBs [6]. Altogether,
the capacity of TRF2 to locally repress Chk2 provides an
additional level of control by which shelterin restrains the
DNA damage response from an unwanted activation [6, 7]
and may explain why TRF2 overexpression acts as a telome-
rase-independent oncogenic stimulus [8].
Results and Discussion
Telomeres are nucleoprotein structures that protect chromo-
some ends. In mammalian cells, this protection is afforded
by the shelterin complex [1], which accumulates on telomeric
DNA, hiding chromosome ends from being recognized as sites
of DNA damage and avoiding the activation of a DNA damage
response (DDR) and inappropriate DNA processing [2]. The
shelterin subunit TRF2 plays a key role in suppressing the telo-
mere-associated DDR through its binding to and inhibition of
ATM kinase [6, 7]. ATM is the apical kinase that in response
to few DSBs activates many subpathways of the DDR [9].
Although it has been proposed that shelterin inhibits the
DDR at telomeres and not elsewhere in the genome, this
attractive proposal remains elusive because ATM is not
detectable at telomeres.
The checkpoint kinase Chk2 is phosphorylated by ATM on
the S/TQ domain upon DNA damage, thereby promoting
Chk2 activation and phosphorylation of molecules involved in
transient cell cycle arrest, apoptosis, and senescence [4].
Recent studies have implicated the DDR in senescence, with
*Correspondence: domenico.delia@istitutotumori.mi.itATM and Chk2 playing a key role in replicative- and onco-
gene-induced senescence [10, 11]. These findings have promp-
ted us to investigate the interplay between TRF2 and Chk2 in
senescence, specifically whether Chk2, like ATM, was inhibited
by TRF2 and whether this occurred at chromosome ends.
To explore whether TRF2 and Chk2 physically interacted
in vivo, reciprocal coimmunoprecipitation (co-IP) analysis
were performed with lysates from undamaged BJ-hTERT
immortalized fibroblasts, which revealed (Figure 1A) the exis-
tence of an endogenous Chk2/TRF2 complex. Similar findings
were seen in LCL normal cells, U2OS and IOSE80 cancer cells
(data not shown), thus excluding a cell type specificity for this
interaction. This association was also confirmed by pull-down
assays with GST-Chk2 and GST-TRF2 that were able to
precipitate TRF2 and Chk2 from LCL cell extracts, respectively
(Figure S1 available online).
To further substantiate the Chk2/TRF2 binding, we assessed
other shelterin subunits in undamaged cells and found that
RAP1 and TRF1 [1] co-IP with endogenous Chk2 (Figure 1B).
The specificity of these interactions was confirmed by the
failure of Cdc2 to co-IP RAP1 (Figure S2) and Chk2 to co-IP
the nuclear protein RXRa (Figure 1B; Figure S2). These data
indicate that endogenous Chk2 forms a complex with TRF2,
RAP1, and TRF1.
To determine whether TRF2 and Chk2 interacted directly
and to verify the role of telomeric DNA, binding assays were
performed with recombinant TRF2 and Chk2 wild-type
(Chk2WT) or kinase dead (Chk2KD) incubated with or without
duplex telomeric oligonucleotide repeats. The TRF2 associa-
tion with Chk2 was not only direct, but significantly enhanced
by telomeric DNA (Figure 1C, compare lanes 2–3 and 4–5).
Furthermore, TRF2 interacted more strongly with Chk2KD
than with Chk2WT (Figure 1C, compare lane 3 with 5), suggest-
ing a negative role for active Chk2.
The telomeric localization of Chk2 was assessed by immu-
nofluorescence (IF) analysis, after validation of antibodies
(Figures S3, S4A, and S4B). As telomeric marker, instead of
TRF2 we assessed RAP1 because of the bright fluorescence
signal it generated in the experimental conditions used here,
which required detergent extraction to remove weakly bound
or nuclear diffuse Chk2 (Figure S4C for Chk2 IF staining in
pre-extraction condition, Figure S4D for RAP1-TRF2 colocali-
zation). In BJ-hTERT cells, the Chk2 fluorescent dots, though
faint, mostly colocalized with RAP1 (Figure 1D), consistent
with Chk2 being on telomeres. In contrast to the shelterin
components, Chk2 was not detected on all telomeres, similar
to other telomeric proteins such as Rad50 [12]. Whether this
reflects the highly mobile nature of Chk2 in cells [13] is a possi-
bility. These colocalizations with RAP1 were more evident in
BJ-hTERT overexpressing Chk2KD than Chk2WT (Figure 1D),
suggesting that activity of Chk2 modulates its telomeric local-
ization. Importantly, Chk2 on telomeres were negative for
g-H2AX (Figure 1D, bottom), indicating that Chk2 resides on
normal and not dysfunctional telomeres, the latter known to
elicit a canonical DDR and accumulation of g-H2AX at chromo-
some ends [10]. These results, besides showing a TRF2/Chk2
interaction in vivo, provide the first direct evidence for a
DDR signaling kinase at telomeres, considering that the
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875Figure 1. Chk2 Physically Interacts with TRF2 on Telomeres
(A) Immunoprecipitations (IPs) were performed on BJ-hTERT extracts with antibodies against Chk2 (left) or TRF2 (right) and immunoblotted (IB) with the
indicated antibodies.
(B) Western blot analysis of Chk2 IPs from BJ-hTERT cell extracts tested with antibodies against RAP1, TRF1, Chk2, and RXRa. RXRa was used as an
additional negative control (see also Figure S2 for similar experiments with additional negative controls).
(C) Pull-down analysis performed with sepharose-bound GST-Chk2WT or GST-Chk2KD, and His-TRF2 previously incubated with or without telomeric DNA.
After extensive washing, the complexes were analyzed by western blot with TRF2 or Chk2 antibodies. Pre, preclearing; input, 8% of the total cell lysate.
(D) Upper panels: double-color IF staining for Chk2 and RAP1 in mock, Chk2WT, or Chk2KD expressing BJ-hTERT cells. Cells were treated with detergent (see
Supplemental Experimental Procedures) to extract weakly bound or diffuse Chk2. Nuclei were stained with DAPI. Arrows denote endogenous Chk2/RAP1
colocalizations. Bottom: double-color IF staining for Chk2 and g-H2AX in Chk2KD expressing BJ-hTERT cells. Chk2 IF dots do not colocalize with g-H2AX, as
evidenced in merged picture.
(E) BJ-hTERT cells treated with siRNA targeting TRF2 or a control sequence (siLuc) were tested for TRF2 depletion by western blot (top) and by IF with
antibodies against Chk2 and TRF1. Labeled cells were scored (>100) by fluorescence microscopy and those with more than eight Chk2-TRF1 colocalizing
spots were considered positive. Error bars calculated from three independent experiments. In these experiments TRF1, rather than RAP1, was used to label
telomeres because depletion of TRF2 results in a diffuse expression of RAP1 (whose localization on telomeres depends on TRF2).
(F) The same cells in (E) were tested for Chk2-RAP1 interaction. Pre, preclearing; input, 5% of the total IP input.TRF2-targeting kinase ATM has not been detected at telo-
meres [7]. Telomeric Chk2 localization was mainly dependent
on TRF2, as shown by the fact that depletion of TRF2 by siRNA
markedly reduced the fraction of Chk2-TRF1 colocalizations
(Figure 1E), and almost abolished Chk2-RAP1 binding
(Figure 1F).
To map the Chk2/TRF2 interacting regions, co-IPs were per-
formed in U2OS cells expressing wild-type and deletion forms
of FLAG-Chk2 and Myc-TRF2 (Figure S5). Whereas Chk2 lack-
ing the first 17 aa (DN1-17) and 42 aa (DN1-42) or the fork-head
domain (DFHA) (a phosphoprotein-binding module) preservedthe interaction with TRF2, Chk2 lacking the S/TQ (DS/TQ)
alone or together with the FHA domain (DS/TQ-DFHA) lost
the interaction (Figure 2A). Furthermore, the TRF2DBDM lacking
both Basic (B) and Myb (M) domains, the former involved in
binding to DNA junctions [6], the latter in the interaction with
telomeric TTAGGG repeats [14], failed to bind Chk2
(Figure 2B), whereas TRF2DB lacking the Basic domain only
(a truncated protein mainly localized on telomeres [14]) weakly
interacted with Chk2 (Figure 2B). Thus, the Chk2 S/TQ and
the TRF2 Myb domains are crucial for their binding and confirm
an interaction preferentially occurring on telomeres. These
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876Figure 2. The S/TQ and Myb Domains of Chk2
and TRF2, Respectively, Mediate the Interaction
between These Proteins
Extracts were prepared from U2OS cells tran-
siently expressing full-length or deleted forms
of Myc-TRF2 and FLAG-Chk2 (see Figure S5 for
detailed amino acid deletions). For each extract,
5% of the total IPs input was western blotted
with an Flag antibody ([A], top). Anti-FLAG immu-
noprecipitates from these cell extracts were
immunoblotted with antibodies against Myc and
FLAG ([A], bottom). The corresponding preclear-
ings, immunoblotted on a separate gel, were
tested with an Myc antibody (as negative
control). The asterisk denotes a nonspecific
band. Western blot analysis of lysates from
U2OS cells expressing Myc-TRF2 constructs
([B], top). TRF2 immunoprecipitated from these
cells with an Myc antibody was immunoblotted
with antibodies against Chk2 and Myc ([B],
bottom). Inputs, 5% of the total extract; pre,
preclearing; IP, immunoprecipitate.findings raise the possibility that TRF2 binding to the S/TQ
might preclude phosphorylation of this domain or hinder
Chk2 dimerization and subsequent autophosphorylation,
essential steps for Chk2 activation [15]. These repression
mechanisms might be similar to those described for ATM [7],
suggesting the presence of a conserved activity in the TRF2-
dependent inhibition of DDR.
Upon DNA damage, ATM phosphorylates Chk2 on threonine
68 (T68) located in the S/TQ domain [15], leading to its activa-
tion by auto/transphosphorylation at several additional sites
including threonine 387 (T387) [15, 16]. Of note, overexpressed
Chk2, while undergoing similar modifications, is constitutively
active in the absence of DNA damage [15]. TRF2 might antag-
onize Chk2 by blocking its activation process, so we moni-
tored the phosphorylation of Chk2 on T68 and T387 in
BJ-hTERT-overexpressing Chk2. Quite interestingly, the
fraction of phosphorylated Chk2 relative to the total amount
was considerably reduced in cells stably expressing TRF2
(Figure S6) at 6 and 32 days after Chk2 transfection
(Figure 3A), indicating that TRF2 interferes with Chk2 phos-
phorylation. Neither KU-55933 nor caffeine, inhibitors of ATM
and ATM/ATR, respectively [9, 17], affected the phosphoryla-
tion of ectopic Chk2-T68 (Figure 3B), thus excluding the inhib-
itory effect of TRF2 on ATM as the mechanism responsible for
reduced Chk2 phosphorylation. Likewise, GW843682 [18], an
inhibitor of PLKs that targets Chk2, had no effect on T68 phos-
phorylation (Figure 3B). To verify the role of DNA-PK, we tested
the effects of wortmannin and SU11752 inhibitors. The former
works by forming a covalent adduct with the catalytic domain
of PI-3 kinases and the dose used here is specific for DNA-PK
[19]; the latter selectively inhibits DNA-PK by ATP competition
[20]. Both agents markedly attenuated Chk2-T68 phosphoryla-
tion (Figure 3B). Ectopic Chk2 did not trigger the activation of
DNA-PKcs, ATM, or ATR (Figure S7), so these results would
suggest that the phosphorylation of Chk2 is mediated by the
basal activity of DNA-PKcs, which would agree with Chk2
being an effective substrate for DNA-PKcs [21, 22] and with
a detectable basal DNA-PK activity in unstressed cells [23].
Intriguingly, DNA-PKcs is involved in telomere homeostasis,
in signaling short telomeres as DNA damage, and in functional
interaction with TRF1 and TRF2 [24]. If DNA-PKcs was actually
implicated in Chk2 activation, then TRF2 might have been
expected to block Chk2 by inhibiting DNA-PKcs. However,the autophosphorylation of DNA-PKcs-S2056 in TRF2-overex-
pressing BJ-hTERT cells was not inhibited either before or
after IR, whereas conversely the activity of ATM, assessed
by the phosphorylation of its substrate SMC1-S996, was
strongly repressed (Figure S8). Therefore, in overexpression
conditions, the TRF2-mediated inhibition of Chk2 phosphory-
lation is not consequent to the suppression of ATM or
DNA-PKcs.
To determine whether endogenous TRF2 inhibited Chk2
locally on telomeres, we evaluated by IF the phosphorylation
of Chk2KD on T68. Despite being constitutively phosphory-
lated on T68 [16], the fraction of telomeric Chk2KD molecules
were unphosphorylated (Figure 3C), confirming the ability of
TRF2 to locally repress Chk2.
The major biological effect of ectopic Chk2WT in BJ-hTERT
cells was, as reported [5], the induction of senescence and
senescence-associated marker b-galactosidase in >50% and
27% of cells at 6 and 32 days, respectively (Figure 3D). Similar
findings were seen in U2OS cells (data not shown), which use
ALT to maintain telomeres, indicating that Chk2 induces
senescence irrespective of telomere length and elongation
mechanism. TRF2 expression in BJ-hTERT cells markedly
antagonized Chk2-induced senescence up to 32 days after
transfection (Figure 3D). KU-55933 did not abrogate senes-
cence (Figure S9), demonstrating that the TRF2-mediated
inhibition of Chk2 was not ensuing from ATM repression.
These data well fit with the aforementioned TRF2-dependent
and ATM-independent repression of Chk2 (Figure 3B). Oxida-
tive stress, a major contributor to DNA damage and senes-
cence, was not required for Chk2-induced senescence,
according to the comparable b-galactosidase positivity of
cells grown in hypoxic and normoxic conditions (Figure S9).
Chk2 overexpression resulted in a growth inhibition that was
attenuated by TRF2 expression (Figure S9; Chk2 alone,
S+G2/M = 13%; Chk2 plus TRF2, S+G2/M = 27%), but in
contrast to its apoptotic activity in some cancer cells [5], it
did not have such effect in BJ-hTERT (Figure S9).
The endogenous activation of Chk2 by ATM involves in
trans- and autophosphorylation steps occurring within 3 hr
[15]. To determine whether TRF2 affected these events,
co-IP experiments were performed at different times after IR.
The TRF2/Chk2 binding seen in undamaged cells was lost at
3 hr, but not 30 min after IR (Figure 4A), suggesting that
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877Figure 3. TRF2 Represses Chk2 Phosphorylation
and Chk2-Induced Senescence
(A) Chk2 phosphorylation on T68 and T387 was
evaluated by western blot in mock, Chk2, TRF2,
or Chk2/TRF2 expressing BJ-hTERT cells.
Lysates were prepared from these cells at 6 and
32 days after being transduced with Chk2.
(B) The phosphorylation of T68 was evaluated
by western blot in BJ-hTERT cells transiently
expressing Chk2 and treated for 48 hr with the
indicated inhibitors (Ve, vehicle; KU, KU-55933;
Caff, caffeine; Wort, wortmannin; SU, SU11752;
GW, GW843682). Error bars calculated from three
independent experiments.
(C) IF analysis of Chk2 in combination with
RAP1 and phospho-T68 in Chk2KD expressing
BJ-hTERT. Cells were treated with detergent to
extract free Chk2. Chk2 small dots do not coloc-
alize with phospho-T68 as evidenced by arrows
that mark representative Chk2-RAP1 colocaliz-
ing spots, demonstrating that telomeric Chk2 is
unphosphorylated. Nuclei were stained with
DAPI.
(D) BJ-hTERT cells stably expressing TRF2 (or
a mock control) were transduced with a plasmid
expressing Chk2 and assessed for b-galactosi-
dase positivity 6, 20, and 32 days later. The
data in the histogram were obtained from three
independent experiments 6 SD. Representative
images of cells at day 6 are shown.upon DNA damage endogenous Chk2 is displaced from telo-
meres. To verify the role played by enzymatic activity of
Chk2, IF analyses were performed in BJ-hTERT expressing
Chk2WT or Chk2KD. Before damage, both Chk2WT and Chk2KD
were found at telomeres (Figure 4B), though the former
showed a faint signal, as reported above (Figure 1D), but after
IR the telomeric dots dropped in the case of Chk2KD and
became undetectable in the case of Chk2WT (Figure 4B).
Therefore, DNA damage and catalytic activity both enhance
the dissociation of Chk2 from telomeres, in accordance with
the in vitro binding assays (Figure 1C). Chromatin remodelling
did not contribute to telomeric dissociation of Chk2, because
in Chk2KD-expressing cells, neither hypotonic stress nor tri-
chostatin A, both inducing chromatin remodelling and ATM
activation, affected Chk2 (Figure S10).
The stronger binding of TRF2 to Chk2KD than to Chk2WT
prompted us to verify whether Chk2 catalyzes the phosphoryla-
tion of TRF2. In vitro, TRF2 was phosphorylated by recombinant
Chk2 (Figure 4C) on residues located in the first 350 aa
(Figure S11). Because this fragment contains on Ser20
a consensus motif (RxxS) for Chk2, we generated a TRF2
substrate carrying a Ser to Ala substitution at aa 20 (S20A),
but its phosphorylation was not abrogated or attenuated
(Figure S11, right) suggesting the involvement of other resi-
due(s). It should be noted that not all in vivo targets of Chk2
are phosphorylated on residues matching the RxxS motif
(e.g., Brca1, p53, Rb, Xrcc1, TTK). Importantly, in vivo a fraction
of the TRF2 molecules appeared phosphorylated on serine in
a Chk2-dependent manner, as evident from the phosphoserine
signal detected on TRF2 immunoprecipitated from control (si-
Luc) and Chk2-depleted (siChk2) irradiated cells (Figure 4D).Similar results were seen in extracts from irradiated cells
cultured with or without the Chk2 inhibitor VRX0466617 [25]
(Figure S12). To evaluate whether Chk2 activity affected the
binding of TRF2 for telomeric TTAGGG repeats in duplex DNA,
electrophoretic mobility shift assays (EMSA) were performed
in the presence of ATP to allow phosphorylation (Figure S13
shows the specificity of TRF2 binding to telomeric DNA in the
assay conditions) and found that in contrast to Chk2KD, Chk2WT
decreased the binding of TRF2 to DNA (Figure 4E). This was not
attributable to the formation of a Chk2/TRF2 complex (data not
shown). Besides, TRF2 interacted more strongly with Chk2KD
than with Chk2WT (Figure 1C). Of note, in vivo the telomeric
binding of TRF2 and of its direct interactor RAP1 was not
affected by overexpressed Chk2WT, according to immunoblots
of cell lysates fractionated in extraction buffers containing
50–450 mM KCl (Figure 4F). Hence, although ATM plays an
essential role in TRF2 delocalization [6], we cannot as yet
ascribe to Chk2 a similar function in vivo.
Altogether, these findings draw an analogy between Chk2
and ATM in the interplay with TRF2, with TRF2 being an inhib-
itor of ATM [6, 7] and of Chk2 and a substrate of ATM after DNA
damage [26] and Chk2. These data underline the level of
redundancy and complexity in the ATM-Chk2 pathway,
because ATM and Chk2 share not only activation but also
repression mechanisms. TRF2 represents an additional
example of target substrate common to both ATM and Chk2,
like HdmX, E2F1, BRCA1, and Che-1.
Our worksupports theviewthatshelterin avoids the activation
of the canonical DDR in two ways, by concealing chromosome
ends probably by maintaining telomeric t-loops [1] and by re-
pressing the ATM-Chk2 signaling pathway at normal telomeres.
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878Figure 4. DSBs Disrupt TRF2/Chk2 Interaction, whereas Chk2 Phosphorylates TRF2 and Reduces TRF2 Binding to Telomeric DNA
(A) Chk2 immunoprecipitates from LCL cells harvested before, 30 min after, and 3 hr after 6Gy were tested for TRF2 by western blotting.
(B) BJ-hTERT cells expressing Chk2WT or Chk2KD were treated with 20Gy IR and 75 min later fixed and labeled by double-color IF with Chk2 (green)
and RAP1 (red) antibodies.
(C) Autoradiographs of in vitro Chk2 kinase assays performed in the presence of active GST-Chk2 and full-length His-TRF2. Cdc25C served as a positive
control substrate. Chk2 autophosphorylation is also detectable. The Coomassie-stained gels evidence the loaded proteins per sample.
(D) TRF2 immunoprecipitated from U2OS cells transfected for 48 hr with siLuc or siChk2, treated with 20Gy IR 2 hr, and collected 2 hr later, was western
blotted with antibodies against phospho-Serine and Myc (for normalization). Input, 5% of the total cell lysate; pre, preclearing; IP, immunoprecipitate.
(E) EMSA performed in presence of TRF2, Chk2WT, or Chk2KD and telomeric DNA (see Figure S13 and Supplemental Experimental Procedures). The graph
shows the quantification of bound and free DNA from three independent experiments 6 SD.
(F) Mock and Chk2-transfected U2OS cells were lysed with an extraction buffer containing 50 mM up to 450 mM KCl. 450p indicates the pellet obtained
from 450 mM KCl lysis.TRF2 might repress ATM and Chk2 by a common mechanism
involving the binding to the kinases’ critical segments (the S/TQ
region of Chk2 spanning T68, and the ATM region spanning
S1981) thereby constraining key steps in their activation.
Finally, the suppression by TRF2 of the ATM/Chk2 pathway,
whose integrity is essential for DNA damage surveillance and
genome stability [27], further supports the view that TRF2
acts as a potently oncogenic stimulus in vivo, independently
of telomerase activity [8], and explains the TRF2 overexpres-
sion in certain cancers [28].
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